Liver stiffness measurements in patients with metabolic dysfunction-associated steatotic liver disease: Updates on the method effectiveness and perspectives

代谢功能障碍相关脂肪肝患者的肝脏硬度测量:方法有效性和展望的最新进展

阅读:3

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most widespread chronic liver disease signified by serious life-threatening conditions. The prevalence of MASLD increases along the growing prevalence in obesity and metabolic syndrome. To minimize costs and complications, non-invasive diagnostic tools, including transient elastography (TE), were introduced for assessment of MASLD. TE measures liver stiffness (LS), a clinical marker for the diagnosis of liver fibrosis and cirrhosis. LS measurements are based on ultrasound wave imaging and quantification. Vibration-controlled TE, including FibroScan(®), is commonly used TE methods which can accurately identify the degree of liver fibrosis and cirrhosis progression. TE was reported to predict the progression towards hepatocellular carcinoma, portal hypertension, and varices. However, the accuracy of LS diagnostics alone in patients with MASLD remains controversial. TE measurements have several limitations, including inadequate precision due to focal liver lesions, cholestasis, inflammation, and other pathological and anatomical factors which can lead to the stiffness variability. Overestimations of TE readings were reported in obese patients with body mass index (BMI) over 30 kg/m(2), and older patients with ascites, diabetes, or hypertension. Not all MASLD patients have high BMI. The prevalence of obesity among MASLD patients varies worldwide, indicating the urgent need for comprehensive diagnostic tools. In patients with MASLD, improved diagnostic accuracy has been demonstrated by combining LS measurements with other blood test-based scores and simple clinical parameters (agile scores based on age, sex, platelet count, aminotransferases, and diabetes). This study reviews the limitations of TE-based diagnostics and discusses the combined scoring algorithm. In conclusion, the sequence of LS measurements along assessment of other important clinical markers is an effective, low-cost, reliable tool to identify and monitor fibrosis progression in MASLD.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。